Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 109

1.

Bevacizumab reduces permeability and concurrent temozolomide delivery in a subset of patients with recurrent glioblastoma.

Gerstner E, Emblem KE, Chang K, Vakulenko-Lagun B, Yen YF, Beers AL, Dietrich J, Plotkin SR, Catana C, Hooker JM, Duda DG, Rosen B, Kalpathy-Cramer J, Jain RK, Batchelor T.

Clin Cancer Res. 2019 Sep 26. pii: clincanres.1739.2019. doi: 10.1158/1078-0432.CCR-19-1739. [Epub ahead of print]

PMID:
31558474
2.

A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases.

Leone JP, Duda DG, Hu J, Barry WT, Trippa L, Gerstner ER, Jain RK, Tan S, Lawler E, Winer EP, Lin NU, Tolaney SM.

Breast Cancer Res Treat. 2019 Sep 20. doi: 10.1007/s10549-019-05445-z. [Epub ahead of print]

PMID:
31541381
3.

Publisher Correction: Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI.

Ly KI, Vakulenko-Lagun B, Emblem KE, Ou Y, Da X, Betensky RA, Kalpathy-Cramer J, Duda DG, Jain RK, Chi AS, Plotkin SR, Batchelor TT, Sorensen G, Rosen BR, Gerstner ER.

Sci Rep. 2019 Jun 14;9(1):8721. doi: 10.1038/s41598-019-44365-2.

4.

Automatic assessment of glioma burden: a deep learning algorithm for fully automated volumetric and bidimensional measurement.

Chang K, Beers AL, Bai HX, Brown JM, Ly KI, Li X, Senders JT, Kavouridis VK, Boaro A, Su C, Bi WL, Rapalino O, Liao W, Shen Q, Zhou H, Xiao B, Wang Y, Zhang PJ, Pinho MC, Wen PY, Batchelor TT, Boxerman JL, Arnaout O, Rosen BR, Gerstner ER, Yang L, Huang RY, Kalpathy-Cramer J.

Neuro Oncol. 2019 Nov 4;21(11):1412-1422. doi: 10.1093/neuonc/noz106.

PMID:
31190077
5.

Dose diversification in newly diagnosed glioblastoma.

Gerstner ER.

Neuro Oncol. 2019 Jun 10;21(6):701-702. doi: 10.1093/neuonc/noz063. No abstract available.

PMID:
30957855
6.

Solid stress in brain tumours causes neuronal loss and neurological dysfunction and can be reversed by lithium.

Seano G, Nia HT, Emblem KE, Datta M, Ren J, Krishnan S, Kloepper J, Pinho MC, Ho WW, Ghosh M, Askoxylakis V, Ferraro GB, Riedemann L, Gerstner ER, Batchelor TT, Wen PY, Lin NU, Grodzinsky AJ, Fukumura D, Huang P, Baish JW, Padera TP, Munn LL, Jain RK.

Nat Biomed Eng. 2019 Mar;3(3):230-245. doi: 10.1038/s41551-018-0334-7. Epub 2019 Jan 7.

7.

Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI.

Ly KI, Vakulenko-Lagun B, Emblem KE, Ou Y, Da X, Betensky RA, Kalpathy-Cramer J, Duda DG, Jain RK, Chi AS, Plotkin SR, Batchelor TT, Sorensen G, Rosen BR, Gerstner ER.

Sci Rep. 2018 Nov 20;8(1):17062. doi: 10.1038/s41598-018-34820-x. Erratum in: Sci Rep. 2019 Jun 14;9(1):8721.

8.

The Use of Quantitative Imaging in Radiation Oncology: A Quantitative Imaging Network (QIN) Perspective.

Press RH, Shu HG, Shim H, Mountz JM, Kurland BF, Wahl RL, Jones EF, Hylton NM, Gerstner ER, Nordstrom RJ, Henderson L, Kurdziel KA, Vikram B, Jacobs MA, Holdhoff M, Taylor E, Jaffray DA, Schwartz LH, Mankoff DA, Kinahan PE, Linden HM, Lambin P, Dilling TJ, Rubin DL, Hadjiiski L, Buatti JM.

Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):1219-1235. doi: 10.1016/j.ijrobp.2018.06.023. Epub 2018 Jun 30. Review.

9.

Phase I and Biomarker Study of Plerixafor and Bevacizumab in Recurrent High-Grade Glioma.

Lee EQ, Duda DG, Muzikansky A, Gerstner ER, Kuhn JG, Reardon DA, Nayak L, Norden AD, Doherty L, LaFrankie D, Stefanik J, Vardam T, Smith KH, McCluskey C, Gaffey S, Batchelor TT, Jain RK, Wen PY.

Clin Cancer Res. 2018 Oct 1;24(19):4643-4649. doi: 10.1158/1078-0432.CCR-18-1025. Epub 2018 Jun 25.

10.

The Role of Advanced Brain Tumor Imaging in the Care of Patients with Central Nervous System Malignancies.

Ly KI, Gerstner ER.

Curr Treat Options Oncol. 2018 Jun 21;19(8):40. doi: 10.1007/s11864-018-0558-5. Review.

PMID:
29931476
11.

ACRIN 6684: Multicenter, phase II assessment of tumor hypoxia in newly diagnosed glioblastoma using magnetic resonance spectroscopy.

Ratai EM, Zhang Z, Fink J, Muzi M, Hanna L, Greco E, Richards T, Kim D, Andronesi OC, Mintz A, Kostakoglu L, Prah M, Ellingson B, Schmainda K, Sorensen G, Barboriak D, Mankoff D, Gerstner ER; ACRIN 6684 trial group.

PLoS One. 2018 Jun 14;13(6):e0198548. doi: 10.1371/journal.pone.0198548. eCollection 2018.

12.

Resolving the phylogenetic origin of glioblastoma via multifocal genomic analysis of pre-treatment and treatment-resistant autopsy specimens.

Brastianos PK, Nayyar N, Rosebrock D, Leshchiner I, Gill CM, Livitz D, Bertalan MS, D'Andrea M, Hoang K, Aquilanti E, Chukwueke UN, Kaneb A, Chi A, Plotkin S, Gerstner ER, Frosch MP, Suva ML, Cahill DP, Getz G, Batchelor TT.

NPJ Precis Oncol. 2017 Sep 18;1(1):33. doi: 10.1038/s41698-017-0035-9. eCollection 2017.

13.

The impact of surgery on survival after progression of glioblastoma: A retrospective cohort analysis of a contemporary patient population.

Sastry RA, Shankar GM, Gerstner ER, Curry WT.

J Clin Neurosci. 2018 Jul;53:41-47. doi: 10.1016/j.jocn.2018.04.004. Epub 2018 Apr 19.

PMID:
29680441
14.

Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate.

Andronesi OC, Arrillaga-Romany IC, Ly KI, Bogner W, Ratai EM, Reitz K, Iafrate AJ, Dietrich J, Gerstner ER, Chi AS, Rosen BR, Wen PY, Cahill DP, Batchelor TT.

Nat Commun. 2018 Apr 16;9(1):1474. doi: 10.1038/s41467-018-03905-6.

15.

Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma.

Ellingson BM, Abrey LE, Nelson SJ, Kaufmann TJ, Garcia J, Chinot O, Saran F, Nishikawa R, Henriksson R, Mason WP, Wick W, Butowski N, Ligon KL, Gerstner ER, Colman H, de Groot J, Chang S, Mellinghoff I, Young RJ, Alexander BM, Colen R, Taylor JW, Arrillaga-Romany I, Mehta A, Huang RY, Pope WB, Reardon D, Batchelor T, Prados M, Galanis E, Wen PY, Cloughesy TF.

Neuro Oncol. 2018 Aug 2;20(9):1240-1250. doi: 10.1093/neuonc/noy053.

16.

Ependymoma.

Gerstner ER, Pajtler KW.

Semin Neurol. 2018 Feb;38(1):104-111. doi: 10.1055/s-0038-1636503. Epub 2018 Mar 16. Review.

PMID:
29548057
17.

Field of View Normalization in Multi-Site Brain MRI.

Ou Y, Zöllei L, Da X, Retzepi K, Murphy SN, Gerstner ER, Rosen BR, Grant PE, Kalpathy-Cramer J, Gollub RL.

Neuroinformatics. 2018 Oct;16(3-4):431-444. doi: 10.1007/s12021-018-9359-z.

PMID:
29353341
18.

Standard chemoradiation in combination with VEGF targeted therapy for glioblastoma results in progressive gray and white matter volume loss.

Prust ML, Jafari-Khouzani K, Kalpathy-Cramer J, Polaskova P, Batchelor TT, Gerstner ER, Dietrich J.

Neuro Oncol. 2018 Jan 22;20(2):289-291. doi: 10.1093/neuonc/nox217. No abstract available.

19.

Phase 2 and biomarker study of trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma.

Reardon DA, Lassman AB, Schiff D, Yunus SA, Gerstner ER, Cloughesy TF, Lee EQ, Gaffey SC, Barrs J, Bruno J, Muzikansky A, Duda DG, Jain RK, Wen PY.

Cancer. 2018 Apr 1;124(7):1438-1448. doi: 10.1002/cncr.31172. Epub 2017 Dec 19.

20.

Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival.

Andronesi OC, Esmaeili M, Borra RJH, Emblem K, Gerstner ER, Pinho MC, Plotkin SR, Chi AS, Eichler AF, Dietrich J, Ivy SP, Wen PY, Duda DG, Jain R, Rosen BR, Sorensen GA, Batchelor TT.

NPJ Precis Oncol. 2017;1. pii: 20. doi: 10.1038/s41698-017-0020-3. Epub 2017 Jun 12.

21.

Residual Convolutional Neural Network for the Determination of IDH Status in Low- and High-Grade Gliomas from MR Imaging.

Chang K, Bai HX, Zhou H, Su C, Bi WL, Agbodza E, Kavouridis VK, Senders JT, Boaro A, Beers A, Zhang B, Capellini A, Liao W, Shen Q, Li X, Xiao B, Cryan J, Ramkissoon S, Ramkissoon L, Ligon K, Wen PY, Bindra RS, Woo J, Arnaout O, Gerstner ER, Zhang PJ, Rosen BR, Yang L, Huang RY, Kalpathy-Cramer J.

Clin Cancer Res. 2018 Mar 1;24(5):1073-1081. doi: 10.1158/1078-0432.CCR-17-2236. Epub 2017 Nov 22.

22.

Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02.

Galanis E, Anderson SK, Miller CR, Sarkaria JN, Jaeckle K, Buckner JC, Ligon KL, Ballman KV, Moore DF Jr, Nebozhyn M, Loboda A, Schiff D, Ahluwalia MS, Lee EQ, Gerstner ER, Lesser GJ, Prados M, Grossman SA, Cerhan J, Giannini C, Wen PY; Alliance for Clinical Trials in Oncology and ABTC.

Neuro Oncol. 2018 Mar 27;20(4):546-556. doi: 10.1093/neuonc/nox161.

23.

ACT IV: the final act for rindopepimut?

Gerstner ER.

Lancet Oncol. 2017 Oct;18(10):1294-1296. doi: 10.1016/S1470-2045(17)30619-8. Epub 2017 Aug 23. No abstract available.

PMID:
28844498
24.

Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials.

Ellingson BM, Gerstner ER, Smits M, Huang RY, Colen R, Abrey LE, Aftab DT, Schwab GM, Hessel C, Harris RJ, Chakhoyan A, Gahrmann R, Pope WB, Leu K, Raymond C, Woodworth DC, de Groot J, Wen PY, Batchelor TT, van den Bent MJ, Cloughesy TF.

Clin Cancer Res. 2017 Oct 1;23(19):5745-5756. doi: 10.1158/1078-0432.CCR-16-2844. Epub 2017 Jun 27.

25.

Case 19-2017 - A 53-Year-Old Woman with Leg Numbness and Weakness.

David WS, Bowley MP, Mehan WA Jr, Shin JH, Gerstner ER, DeWitt JC.

N Engl J Med. 2017 Jun 22;376(25):2471-2481. doi: 10.1056/NEJMcpc1701762. No abstract available.

PMID:
28636859
26.

MRI and PET: Noninvasive Tools to Probe the Biology of Diffuse Intrinsic Pontine Glioma.

Gerstner ER.

J Nucl Med. 2017 Aug;58(8):1262-1263. doi: 10.2967/jnumed.117.192526. Epub 2017 Apr 6. No abstract available.

27.

Accrual Patterns for Clinical Studies Involving Quantitative Imaging: Results of an NCI Quantitative Imaging Network (QIN) Survey.

Kurland BF, Aggarwal S, Yankeelov TE, Gerstner ER, Mountz JM, Linden HM, Jones EF, Bodeker KL, Buatti JM.

Tomography. 2016 Dec;2(4):276-282. doi: 10.18383/j.tom.2016.00169.

28.

Personalized Radiotherapy Planning Based on a Computational Tumor Growth Model.

Le M, Delingette H, Kalpathy-Cramer J, Gerstner ER, Batchelor T, Unkelbach J, Ayache N.

IEEE Trans Med Imaging. 2017 Mar;36(3):815-825. doi: 10.1109/TMI.2016.2626443. Epub 2016 Nov 8.

PMID:
28113925
29.

Reliable estimation of microvascular flow patterns in patients with disrupted blood-brain barrier using dynamic susceptibility contrast MRI.

Hansen MB, Tietze A, Kalpathy-Cramer J, Gerstner ER, Batchelor TT, Østergaard L, Mouridsen K.

J Magn Reson Imaging. 2017 Aug;46(2):537-549. doi: 10.1002/jmri.25549. Epub 2016 Nov 30.

PMID:
27902858
30.

Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma.

Kalpathy-Cramer J, Chandra V, Da X, Ou Y, Emblem KE, Muzikansky A, Cai X, Douw L, Evans JG, Dietrich J, Chi AS, Wen PY, Stufflebeam S, Rosen B, Duda DG, Jain RK, Batchelor TT, Gerstner ER.

J Neurooncol. 2017 Feb;131(3):603-610. doi: 10.1007/s11060-016-2332-5. Epub 2016 Nov 16.

PMID:
27853960
31.

Multimodality imaging and mathematical modelling of drug delivery to glioblastomas.

Boujelben A, Watson M, McDougall S, Yen YF, Gerstner ER, Catana C, Deisboeck T, Batchelor TT, Boas D, Rosen B, Kalpathy-Cramer J, Chaplain MA.

Interface Focus. 2016 Oct 6;6(5):20160039.

32.

Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-β tyrosine kinase inhibitor, in patients with recurrent glioblastoma.

Batchelor TT, Gerstner ER, Ye X, Desideri S, Duda DG, Peereboom D, Lesser GJ, Chowdhary S, Wen PY, Grossman S, Supko JG.

Neuro Oncol. 2017 Apr 1;19(4):567-575. doi: 10.1093/neuonc/now185.

33.

Deformable image registration between pathological images and MR image via an optical macro image.

Ohnishi T, Nakamura Y, Tanaka T, Tanaka T, Hashimoto N, Haneishi H, Batchelor TT, Gerstner ER, Taylor JW, Snuderl M, Yagi Y.

Pathol Res Pract. 2016 Oct;212(10):927-936. doi: 10.1016/j.prp.2016.07.018. Epub 2016 Aug 2.

34.

Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutant IDH glioma patients.

Jafari-Khouzani K, Loebel F, Bogner W, Rapalino O, Gonzalez GR, Gerstner E, Chi AS, Batchelor TT, Rosen BR, Unkelbach J, Shih HA, Cahill DP, Andronesi OC.

Neuro Oncol. 2016 Nov;18(11):1569-1578. Epub 2016 Jul 5.

35.

ACRIN 6684: Assessment of Tumor Hypoxia in Newly Diagnosed Glioblastoma Using 18F-FMISO PET and MRI.

Gerstner ER, Zhang Z, Fink JR, Muzi M, Hanna L, Greco E, Prah M, Schmainda KM, Mintz A, Kostakoglu L, Eikman EA, Ellingson BM, Ratai EM, Sorensen AG, Barboriak DP, Mankoff DA; ACRIN 6684 Trial Group.

Clin Cancer Res. 2016 Oct 15;22(20):5079-5086. Epub 2016 May 16.

36.

MRI Based Bayesian Personalization of a Tumor Growth Model.

Le M, Delingette H, Kalpathy-Cramer J, Gerstner ER, Batchelor T, Unkelbach J, Ayache N.

IEEE Trans Med Imaging. 2016 Oct;35(10):2329-2339. Epub 2016 Apr 29.

PMID:
27164582
37.

Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas.

Blakeley JO, Ye X, Duda DG, Halpin CF, Bergner AL, Muzikansky A, Merker VL, Gerstner ER, Fayad LM, Ahlawat S, Jacobs MA, Jain RK, Zalewski C, Dombi E, Widemann BC, Plotkin SR.

J Clin Oncol. 2016 May 10;34(14):1669-75. doi: 10.1200/JCO.2015.64.3817. Epub 2016 Mar 14.

38.

Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma.

Curry WT Jr, Gorrepati R, Piesche M, Sasada T, Agarwalla P, Jones PS, Gerstner ER, Golby AJ, Batchelor TT, Wen PY, Mihm MC, Dranoff G.

Clin Cancer Res. 2016 Jun 15;22(12):2885-96. doi: 10.1158/1078-0432.CCR-15-2163. Epub 2016 Feb 12.

39.

Mentorship: Stewards of China's future.

Gerstner E.

Nature. 2015 Dec 17;528(7582):427-8. No abstract available.

PMID:
26682340
40.

Glioblastoma care in the elderly.

Jordan JT, Gerstner ER, Batchelor TT, Cahill DP, Plotkin SR.

Cancer. 2016 Jan 15;122(2):189-97. doi: 10.1002/cncr.29742. Epub 2015 Nov 30. Review.

41.

Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate.

Andronesi OC, Loebel F, Bogner W, Marjańska M, Vander Heiden MG, Iafrate AJ, Dietrich J, Batchelor TT, Gerstner ER, Kaelin WG, Chi AS, Rosen BR, Cahill DP.

Clin Cancer Res. 2016 Apr 1;22(7):1632-41. doi: 10.1158/1078-0432.CCR-15-0656. Epub 2015 Nov 3.

42.

Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials.

Ellingson BM, Bendszus M, Boxerman J, Barboriak D, Erickson BJ, Smits M, Nelson SJ, Gerstner E, Alexander B, Goldmacher G, Wick W, Vogelbaum M, Weller M, Galanis E, Kalpathy-Cramer J, Shankar L, Jacobs P, Pope WB, Yang D, Chung C, Knopp MV, Cha S, van den Bent MJ, Chang S, Yung WK, Cloughesy TF, Wen PY, Gilbert MR; Jumpstarting Brain Tumor Drug Development Coalition Imaging Standardization Steering Committee.

Neuro Oncol. 2015 Sep;17(9):1188-98. doi: 10.1093/neuonc/nov095. Epub 2015 Aug 5. Review.

43.

Vascular Magnetic Resonance Imaging in Brain Tumors During Antiangiogenic Therapy--Are We There Yet?

Gerstner ER, Emblem KE, Sorensen GA.

Cancer J. 2015 Jul-Aug;21(4):337-42. doi: 10.1097/PPO.0000000000000128. Review.

PMID:
26222087
44.

Standard chemoradiation for glioblastoma results in progressive brain volume loss.

Prust MJ, Jafari-Khouzani K, Kalpathy-Cramer J, Polaskova P, Batchelor TT, Gerstner ER, Dietrich J.

Neurology. 2015 Aug 25;85(8):683-91. doi: 10.1212/WNL.0000000000001861. Epub 2015 Jul 24.

45.

Repeatability of Standardized and Normalized Relative CBV in Patients with Newly Diagnosed Glioblastoma.

Prah MA, Stufflebeam SM, Paulson ES, Kalpathy-Cramer J, Gerstner ER, Batchelor TT, Barboriak DP, Rosen BR, Schmainda KM.

AJNR Am J Neuroradiol. 2015 Sep;36(9):1654-61. doi: 10.3174/ajnr.A4374. Epub 2015 Jun 11.

46.

Repeatability of Cerebral Perfusion Using Dynamic Susceptibility Contrast MRI in Glioblastoma Patients.

Jafari-Khouzani K, Emblem KE, Kalpathy-Cramer J, Bjørnerud A, Vangel MG, Gerstner ER, Schmainda KM, Paynabar K, Wu O, Wen PY, Batchelor T, Rosen B, Stufflebeam SM.

Transl Oncol. 2015 Jun;8(3):137-46. doi: 10.1016/j.tranon.2015.03.002.

47.

A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma.

Gerstner ER, Ye X, Duda DG, Levine MA, Mikkelsen T, Kaley TJ, Olson JJ, Nabors BL, Ahluwalia MS, Wen PY, Jain RK, Batchelor TT, Grossman S.

Neuro Oncol. 2015 Oct;17(10):1386-92. doi: 10.1093/neuonc/nov085. Epub 2015 May 24.

48.

Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma.

Lu-Emerson C, Duda DG, Emblem KE, Taylor JW, Gerstner ER, Loeffler JS, Batchelor TT, Jain RK.

J Clin Oncol. 2015 Apr 1;33(10):1197-213. doi: 10.1200/JCO.2014.55.9575. Epub 2015 Feb 23.

49.

Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study.

Chheda MG, Wen PY, Hochberg FH, Chi AS, Drappatz J, Eichler AF, Yang D, Beroukhim R, Norden AD, Gerstner ER, Betensky RA, Batchelor TT.

J Neurooncol. 2015 Feb;121(3):627-34. doi: 10.1007/s11060-014-1680-2. Epub 2014 Dec 13.

50.

The Multimodal Brain Tumor Image Segmentation Benchmark (BRATS).

Menze BH, Jakab A, Bauer S, Kalpathy-Cramer J, Farahani K, Kirby J, Burren Y, Porz N, Slotboom J, Wiest R, Lanczi L, Gerstner E, Weber MA, Arbel T, Avants BB, Ayache N, Buendia P, Collins DL, Cordier N, Corso JJ, Criminisi A, Das T, Delingette H, Demiralp Ç, Durst CR, Dojat M, Doyle S, Festa J, Forbes F, Geremia E, Glocker B, Golland P, Guo X, Hamamci A, Iftekharuddin KM, Jena R, John NM, Konukoglu E, Lashkari D, Mariz JA, Meier R, Pereira S, Precup D, Price SJ, Raviv TR, Reza SM, Ryan M, Sarikaya D, Schwartz L, Shin HC, Shotton J, Silva CA, Sousa N, Subbanna NK, Szekely G, Taylor TJ, Thomas OM, Tustison NJ, Unal G, Vasseur F, Wintermark M, Ye DH, Zhao L, Zhao B, Zikic D, Prastawa M, Reyes M, Van Leemput K.

IEEE Trans Med Imaging. 2015 Oct;34(10):1993-2024. doi: 10.1109/TMI.2014.2377694. Epub 2014 Dec 4. Review.

Supplemental Content

Loading ...
Support Center